Notice to attend Extraordinary General Meeting in INQ Group AB (publ)

INQ Group’s board is seeking shareholder approval to convert Tranche 7 convertible-loan claims into shares at SEK 0.16 each, issuing up to 49,181,718 shares, and to restore authority to issue shares, warrants and convertibles within the existing 390 million-share limit. The board says about 339.9 million shares would remain available under the proposed authorisation, equivalent to maximum dilution of approximately 16.9% on the notice’s stated calculation; the proposed Tranche 7 conversions would convert debt into equity. The EGM is scheduled for 30 October 2026, and the resolutions remain subject to shareholder approval.

Analysis

INQ’s key signal is financing quality, not the reverse split: converting accrued compensation and lender claims into shares removes obligations but brings no new cash. It may ease near-term cash pressure, while leaving operating runway dependent on subsequent financing. The broad authority to issue equity, warrants or convertibles creates a persistent supply overhang; instruments with conversion features can make dilution path-dependent, especially if the share price weakens. The 1:100 consolidation changes the unit price and share count, not enterprise value or dilution, and could add trading friction around fractional-share handling.

The headline dilution cap needs careful reconciliation before modeling: the summary cites roughly 16.7%, while the detailed proposal cites 16.9% and uses a pro forma denominator of about 2.013bn shares. Those denominators are not the current share count. Confirm the registered share count, all outstanding conversion obligations and the final share-authority calculation in the meeting documents; do not treat the cap as the full dilution already incurred.

Near term, the October 30 EGM is a binary governance catalyst, particularly the 90% approval threshold for the director/CEO issuance. Over 1–3 months, watch registration, reverse-split timing and any new financing terms. Over 6–18 months, the central risk is repeated issuance without evidence that capital converts into durable revenue or cash generation. Contrarian point: debt conversion can reduce cash claims, but it is not equivalent to fresh funding or proof of an operating inflection. Thesis improves only with disclosed runway and operating cash-flow progress; it weakens if further below-market or highly dilutive financing is required.

Key Decisions for Investors

• Avoid adding ahead of the EGM; first reconcile the 16.7%/16.9% figures and obtain a full, instrument-by-instrument dilution and maturity schedule.
• Treat INQ as a watch rather than a short absent confirmed borrow and liquidity: the financing overhang is adverse, but event-driven microcap trading can make risk control difficult.
• Set a post-EGM alert for registration of Tranche 7 shares, the reverse-split record date and any new warrant/convertible terms. Reassess only alongside cash runway and operating cash-flow disclosure.
• Falsifiers: shareholder rejection of the resolutions, or conversely new capital on terms that materially reduce dilution and extend runway; also track whether subsequent reporting shows improving cash generation rather than merely balance-sheet conversion.